InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (4 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Franck Grimaud, Deputy CEO. Insider active across 1 company, notably VALNEVA SE. Aggregated, 12 filings have been logged. Split: 5 buys · 4 sells. Total volume traded: €5.2m. Activity tracked since 15 December 2021. The latest transaction was filed on 10 October 2024 (Acquisition d'actions gratuites). Regulator: AMF. The full history is accessible without signup.
Companies and markets linked to Franck Grimaud
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
14,844 shares0ActionHors plateforme de négociation2024DD1007273
Canonical exit: 8 Jan 2025 (T+90)
35,009 shares0ActionHors plateforme de négociation2024DD956061
Canonical exit: 16 Jun 2024 (T+90)
34,802 shares0ActionHors plateforme de négociation2024DD944635
87,523 shares0ActionHors plateforme de négociation2023DD899722
Canonical exit: 8 Aug 2023 (T+90)
25,000 shares@ €15.43637.0% of flowActionEuronext Paris2022DD833144
70,018 shares@ €15.100519.3% of flowActionEuronext Paris2022DD832752
87,523 shares0ActionHors plateforme de négociation2022DD832473
Canonical exit: 23 Jun 2022 (T+90)
4,651 shares0ActionEuronext Paris2022DD814898
114,005 shares@ €18.309838.1% of flowActionEuronext Paris2022DD815121
109,962 shares@ €2.9195.9% of flowActionEuronext Paris2022DD815128
87,969 shares@ €18.57129.8% of flowActionEuronext Paris2022DD815132
4,651 shares0ActionHors plateforme de négociation2021DD812846
Canonical exit: 15 Mar 2022 (T+90)
12 of 12 declarations
About Franck Grimaud
Franck Grimaud is one of the co-founders of Valneva SE and a long-standing executive who played a central role in the company’s development. Until his planned departure on June 25, 2025, he served as Associate Managing Officer (Directeur Général Délégué) and Chief Business Officer, after many years in senior operational and commercial leadership roles. Valneva stated that he spent twenty-six years with Vivalis and Valneva and that he made a particularly meaningful contribution to the company’s strategy, especially its commercial vaccine business. Before Valneva’s governance transition, Grimaud had already been a key leader at Vivalis SA, the French biotechnology company that merged with Austria’s Intercell to create Valneva SE in 2013. Valneva’s corporate filings indicate that he was appointed Managing Director (Directeur Général) by the Supervisory Board on May 10, 2013, and later moved into the new leadership structure introduced in December 2023. This continuity highlights his long-term influence on the group’s strategic direction and operational execution. His career has been closely tied to business development, international expansion, and vaccine commercialization. Valneva describes him as having 25 years of corporate business development experience and as the former CEO and co-founder of Vivalis. His background reflects an entrepreneurial trajectory rooted in life sciences and biotechnology, with a strong ability to build businesses, open markets, and support sustainable growth in a specialized vaccine platform. He was also involved in expanding Valneva’s commercial footprint, including the strengthening of distribution and marketing capabilities in key markets. From a governance perspective, Franck Grimaud represents the archetype of a founder-executive with a strong execution mindset and international commercial focus. His legacy at Valneva is associated with company building, value creation, and the scaling of the organization’s commercial vaccine business. His departure in 2025 closes a long entrepreneurial chapter that began with Vivalis and continued through Valneva’s growth as a listed specialty vaccine company.
